Compare GSK plc (GSK) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NetEase Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while NetEase Inc trades at $124.24 (market cap $76.09B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and NetEase Inc for 73 Days on average.
| GSK | NTES | |
|---|---|---|
Market Cap | $91.88B | $76.09B |
Volume | 7,730,529 | 486,447 |
Sector | Health | Technology |
52-Week High | $61.18 | $152.85 |
52-Week Low | $43.24 | $109.26 |
Typical Hold Time | 93 Days | 73 Days |
Enterprise Value | $111.88B | $51.81B |
Dividend Yield | 3.9% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
NetEase (NTES) trades at $119.60, down 0.84% with neutral technical signals. The company maintains strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show mixed results with two misses and one beat. Analyst consensus remains strongly bullish with 82% buy ratings and $168 price target, representing 40% upside potential from current levels.
NTES presents compelling value with reasonable P/E of 15.9 and strong cash flow generation, but faces execution risks from inconsistent earnings performance and competitive pressures in gaming. The stock's current valuation discount to analyst targets offers opportunity, though investors should monitor Q3 2026 results for sustained growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
